Zerit(stavudine)
Zerit (stavudine) is a small molecule pharmaceutical. Stavudine was first approved as Zerit on 1994-06-24. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Stavudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZERIT | Bristol Myers Squibb | N-020412 DISCN | 1994-06-24 | 5 products, RLD |
| ZERIT | Bristol Myers Squibb | N-020413 DISCN | 1996-09-06 | 1 products, RLD |
| ZERIT XR | Bristol Myers Squibb | N-021453 DISCN | 2002-12-31 | 4 products |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF04: Stavudine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR07: Stavudine, lamivudine and nevirapine
HCPCS
No data
Clinical
Clinical Trials
173 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | — | — | — | 1 | — | 1 |
| Hiv | D006678 | — | — | — | — | — | 1 | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | — | — | — | 1 | — | 1 |
| Human herpesvirus 8 | D019288 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Stavudine |
| INN | stavudine |
| Description | Stavudine is a nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase It has a role as an antimetabolite, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral agent. It is an organic molecular entity, a nucleoside analogue and a dihydrofuran. It is functionally related to a thymine. |
| Classification | Small molecule |
| Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 3056-17-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL991 |
| ChEBI ID | 63581 |
| PubChem CID | 18283 |
| DrugBank | DB00649 |
| UNII ID | BO9LE4QFZF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Stavudine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,977 documents
View more details
Safety
Black-box Warning
Black-box warning for: Stavudine, Zerit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,100 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use